cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29835636
title: Low eosinophils and their dynamic as a predictor of death in patients with infections: a systematic review and meta-analysis of cohort studies

description: Eosinophils prognostic significance in predicting mortality has become particularly notable during the COVID-19 pandemic. We aimed to evaluate the prognostic value of peripheral low eosinophil (eosinopenia) with focus on their dynamics (eosinophil recovery) in patients with infections. We searched databases (MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library) and additional sources from inception to 1 December 2023. Cohort studies involving adult patients hospitalized with infections were evaluated using dual-reviewer methodology. Out of 15,066 screened papers, 151 studies met the inclusion criteria, with 107 focused on COVID-19, 14 on sepsis, 9 on <i>Clostridioides difficile</i>, 6 on acute COPD exacerbations, and 17 on other infections. The majority of studies reported significantly lower admission eosinophil levels in non-survivors compared to survivors. Random-effects model meta-analysis showed mean eosinophil difference between deceased and survivors −15.31 (95% CI: −18.72 to −11.90) for COVID-19 and −44.6 (95% CI: −95.62 to 6.41) for sepsis (<i>I</i><sup>2</sup> &gt; 90%). Mortality with eosinopenia showed low certainty of evidence for <i>C. difficile</i> (0 cells/mm³ cut-off: RR 2.35; 95% CI: 1.84–2.99) and very low for COVID-19 when considering different cut-offs (0 cells/mm³: RR 2.37; 95% CI: 1.86–3.01; 20 cells/mm³: RR 2.90; 95% CI: 1.59–5.28; 50 cells/mm³: RR 2.70; 95% CI: 1.33–5.49). Survivors generally showed an increase in eosinophil counts within the first 2–5 days of hospitalization, while the deceased had persistently low levels. Eosinopenia, particularly the trajectory of eosinophil recovery, may serve as a cost-effective and accessible prognostic marker for mortality in patients with infections.
DOI: 10.6084/m9.figshare.29835636.v1
title: Low eosinophils and their dynamic as a predictor of death in patients with infections: a systematic review and meta-analysis of cohort studies

description: Eosinophils prognostic significance in predicting mortality has become particularly notable during the COVID-19 pandemic. We aimed to evaluate the prognostic value of peripheral low eosinophil (eosinopenia) with focus on their dynamics (eosinophil recovery) in patients with infections. We searched databases (MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library) and additional sources from inception to 1 December 2023. Cohort studies involving adult patients hospitalized with infections were evaluated using dual-reviewer methodology. Out of 15,066 screened papers, 151 studies met the inclusion criteria, with 107 focused on COVID-19, 14 on sepsis, 9 on <i>Clostridioides difficile</i>, 6 on acute COPD exacerbations, and 17 on other infections. The majority of studies reported significantly lower admission eosinophil levels in non-survivors compared to survivors. Random-effects model meta-analysis showed mean eosinophil difference between deceased and survivors −15.31 (95% CI: −18.72 to −11.90) for COVID-19 and −44.6 (95% CI: −95.62 to 6.41) for sepsis (<i>I</i><sup>2</sup> &gt; 90%). Mortality with eosinopenia showed low certainty of evidence for <i>C. difficile</i> (0 cells/mm³ cut-off: RR 2.35; 95% CI: 1.84–2.99) and very low for COVID-19 when considering different cut-offs (0 cells/mm³: RR 2.37; 95% CI: 1.86–3.01; 20 cells/mm³: RR 2.90; 95% CI: 1.59–5.28; 50 cells/mm³: RR 2.70; 95% CI: 1.33–5.49). Survivors generally showed an increase in eosinophil counts within the first 2–5 days of hospitalization, while the deceased had persistently low levels. Eosinopenia, particularly the trajectory of eosinophil recovery, may serve as a cost-effective and accessible prognostic marker for mortality in patients with infections.
DOI: 10.6084/m9.figshare.29820299
title: Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis

description: For extensive-stage small cell lung cancer (ES-SCLC) with intrathoracic residuals after chemotherapy, the landmark CREST trial demonstrated the benefit of consolidative thoracic radiotherapy (cTRT). Yet the efficacy and safety of cTRT after chemoimmunotherapy for ES-SCLC remain largely unknown. This study aimed to assess the role of cTRT following chemoimmunotherapy in patients with ES-SCLC. A retrospective analysis of ES-SCLC patients without disease progression after first-line chemoimmunotherapy was conducted between March 2019 and November 2021. Based on whether cTRT or not, patients were allocated to cTRT group or non-cTRT group. We evaluated efficacy by using the median overall survival (mOS) and progression-free survival (mPFS) times, and safety by measuring the incidence of adverse events. During this study, 72 patients with ES-SCLC were enrolled, with a median follow-up of 34.66 months. Twenty-nine patients received cTRT and 43 patients did not receive cTRT. Among the cTRT group and the non-cTRT group, the mPFS was 11.50 and 8.02 months, respectively, with a HR of 0.60 (95% CI 0.36–0.99, <i>p</i> = 0.043). The mOS in the cTRT group was also significantly longer than that in the non-cTRT group (28.68 months vs. 16.30 months, HR = 0.56, 95% CI 0.32–0.96, <i>p</i> = 0.033). Based on multivariate analysis, cTRT and cycles of immunotherapy ≥ 6 were independent factors affecting survival. There were no treatment-related deaths and most adverse events were grade 1–2. This study suggests that the addition of cTRT to first-line chemo­immunotherapy significantly improves survival in ES-SCLC with well-tolerated toxicity. There is a paucity of evidence regarding the efficacy and safety of consolidative thoracic radiotherapy (cTRT) after chemoimmunotherapy for ES-SCLC.We conducted a real-world study to investigate whether cTRT is necessary in patients with ES-SCLC who responded well to chemoimmunotherapy.ES-SCLC patients treated with cTRT after first-line chemoimmunotherapy had prolonged PFS and OS with an acceptable safety profile in our study. There is a paucity of evidence regarding the efficacy and safety of consolidative thoracic radiotherapy (cTRT) after chemoimmunotherapy for ES-SCLC. We conducted a real-world study to investigate whether cTRT is necessary in patients with ES-SCLC who responded well to chemoimmunotherapy. ES-SCLC patients treated with cTRT after first-line chemoimmunotherapy had prolonged PFS and OS with an acceptable safety profile in our study.
DOI: 10.6084/m9.figshare.29820299.v1
title: Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis

description: For extensive-stage small cell lung cancer (ES-SCLC) with intrathoracic residuals after chemotherapy, the landmark CREST trial demonstrated the benefit of consolidative thoracic radiotherapy (cTRT). Yet the efficacy and safety of cTRT after chemoimmunotherapy for ES-SCLC remain largely unknown. This study aimed to assess the role of cTRT following chemoimmunotherapy in patients with ES-SCLC. A retrospective analysis of ES-SCLC patients without disease progression after first-line chemoimmunotherapy was conducted between March 2019 and November 2021. Based on whether cTRT or not, patients were allocated to cTRT group or non-cTRT group. We evaluated efficacy by using the median overall survival (mOS) and progression-free survival (mPFS) times, and safety by measuring the incidence of adverse events. During this study, 72 patients with ES-SCLC were enrolled, with a median follow-up of 34.66 months. Twenty-nine patients received cTRT and 43 patients did not receive cTRT. Among the cTRT group and the non-cTRT group, the mPFS was 11.50 and 8.02 months, respectively, with a HR of 0.60 (95% CI 0.36–0.99, <i>p</i> = 0.043). The mOS in the cTRT group was also significantly longer than that in the non-cTRT group (28.68 months vs. 16.30 months, HR = 0.56, 95% CI 0.32–0.96, <i>p</i> = 0.033). Based on multivariate analysis, cTRT and cycles of immunotherapy ≥ 6 were independent factors affecting survival. There were no treatment-related deaths and most adverse events were grade 1–2. This study suggests that the addition of cTRT to first-line chemo­immunotherapy significantly improves survival in ES-SCLC with well-tolerated toxicity. There is a paucity of evidence regarding the efficacy and safety of consolidative thoracic radiotherapy (cTRT) after chemoimmunotherapy for ES-SCLC.We conducted a real-world study to investigate whether cTRT is necessary in patients with ES-SCLC who responded well to chemoimmunotherapy.ES-SCLC patients treated with cTRT after first-line chemoimmunotherapy had prolonged PFS and OS with an acceptable safety profile in our study. There is a paucity of evidence regarding the efficacy and safety of consolidative thoracic radiotherapy (cTRT) after chemoimmunotherapy for ES-SCLC. We conducted a real-world study to investigate whether cTRT is necessary in patients with ES-SCLC who responded well to chemoimmunotherapy. ES-SCLC patients treated with cTRT after first-line chemoimmunotherapy had prolonged PFS and OS with an acceptable safety profile in our study.
DOI: 10.6084/m9.figshare.30179022
title: Customized protective palatal obturator for intubation in newborns in cleft lip surgery: a randomized controlled trial

description: Orofacial clefts are common congenital malformations, affecting both facial aesthetics and function. Intubation in newborns with cleft lip and palate is challenging and carries a high risk of oral tissue damage. This study investigates the use of a customized protective palatal obturator (CPPO) to improve intubation safety and reduce tissue injury during cleft lip surgery. A single-center, randomized neonatal sub-study was conducted, including 55 newborns who underwent cleft lip surgery. Patients were randomized into an intervention group (CPPO use) and a control group (standard intubation without CPPO). The primary aim was to evaluate the degree of oral tissue injury during intubation, its severity, and location, in both groups, secondary aims included laryngoscopy image during intubation (modified Cormack-Lehane scoring system), intubation time, and attempts, number of intubations attempts and anesthesiologic complication during intubation. This study was registered on www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04422847 and NCT04422964). No tissue damage occurred in the CPPO group, while the control group had a 21.4% incidence of tissue injury (<i>p</i> = .023). Secondary outcomes showed no statistically significant differences between groups for intubation time or the number of intubation attempts. Difficult intubation was less frequent in the CPPO group (40.7%) compared to the control group (50%), though this difference was not statistically significant. The CPPO significantly reduces the risk of tissue damage during intubation in newborns undergoing cleft lip surgery, without increasing intubation time or attempts. It is particularly beneficial for severe clefts, and its use may facilitate safer airway management in these high-risk patients. Customized protective palatal obturators enhance intubation safety in newborns with cleft lip, alveolus and palate.The customized protective palatal obturator is especially advantageous for patients with more severe clefts, offering better protection against tissue damage during intubation.The customized protective palatal obturator does not prolong intubation time or increase the number of intubation attempts, making it an effective tool for better airway management without added difficulty or delay. Customized protective palatal obturators enhance intubation safety in newborns with cleft lip, alveolus and palate. The customized protective palatal obturator is especially advantageous for patients with more severe clefts, offering better protection against tissue damage during intubation. The customized protective palatal obturator does not prolong intubation time or increase the number of intubation attempts, making it an effective tool for better airway management without added difficulty or delay.
DOI: 10.6084/m9.figshare.30179022.v1
title: Customized protective palatal obturator for intubation in newborns in cleft lip surgery: a randomized controlled trial

description: Orofacial clefts are common congenital malformations, affecting both facial aesthetics and function. Intubation in newborns with cleft lip and palate is challenging and carries a high risk of oral tissue damage. This study investigates the use of a customized protective palatal obturator (CPPO) to improve intubation safety and reduce tissue injury during cleft lip surgery. A single-center, randomized neonatal sub-study was conducted, including 55 newborns who underwent cleft lip surgery. Patients were randomized into an intervention group (CPPO use) and a control group (standard intubation without CPPO). The primary aim was to evaluate the degree of oral tissue injury during intubation, its severity, and location, in both groups, secondary aims included laryngoscopy image during intubation (modified Cormack-Lehane scoring system), intubation time, and attempts, number of intubations attempts and anesthesiologic complication during intubation. This study was registered on www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04422847 and NCT04422964). No tissue damage occurred in the CPPO group, while the control group had a 21.4% incidence of tissue injury (<i>p</i> = .023). Secondary outcomes showed no statistically significant differences between groups for intubation time or the number of intubation attempts. Difficult intubation was less frequent in the CPPO group (40.7%) compared to the control group (50%), though this difference was not statistically significant. The CPPO significantly reduces the risk of tissue damage during intubation in newborns undergoing cleft lip surgery, without increasing intubation time or attempts. It is particularly beneficial for severe clefts, and its use may facilitate safer airway management in these high-risk patients. Customized protective palatal obturators enhance intubation safety in newborns with cleft lip, alveolus and palate.The customized protective palatal obturator is especially advantageous for patients with more severe clefts, offering better protection against tissue damage during intubation.The customized protective palatal obturator does not prolong intubation time or increase the number of intubation attempts, making it an effective tool for better airway management without added difficulty or delay. Customized protective palatal obturators enhance intubation safety in newborns with cleft lip, alveolus and palate. The customized protective palatal obturator is especially advantageous for patients with more severe clefts, offering better protection against tissue damage during intubation. The customized protective palatal obturator does not prolong intubation time or increase the number of intubation attempts, making it an effective tool for better airway management without added difficulty or delay.
DOI: 10.6084/m9.figshare.30284521
title: Association of the systemic immune inflammation index with failure after core decompression for osteonecrosis of the femoral head: a prospective time-to-event analysis

description: This study aimed to assess the association between preoperative systemic immune inflammation index (SII) and failure after core decompression (CD). We conducted a prospective study of patients admitted to a tertiary referral hospital with osteonecrosis of the femoral head who underwent CD between October 1, 2014 and April 30, 2019, and provided a minimum 3-year follow-up assessment. Restricted cubic splines assessed the dose–effect relationship between SII and failure. Propensity score matching (PSM) balanced potential preoperative confounders. Kaplan–Meier analyses estimated cumulative incidence as a function of time for the failure between low SII and high SII groups. Multivariable Cox proportional hazards models evaluated the independent association of high SII with failure after adjustment for perioperative factors. Prespecified subgroup analyses explored heterogeneity. We found a positive relationship between the preoperative SII and failure after CD. Among 963 CD procedures performed in 676 patients, failure was observed in 97 cases in a median period of 5.4 years. The cumulative incidence of failure was 10.6% (95% CI, 8.7%, 12.8%) at 5 years. After PSM, failure rates at 5 years were identified as significant differences between the high SII and low SII groups (Log-rank p = 0.019), and that high SII was independently associated with a 1.90-fold (95% CI, 1.14, 3.18; p = 0.014) increased risk of failure. Significant heterogeneity was observed by gender and aetiology (P for interaction &lt; 0.05). Preoperative high SII is a significant risk factor for failure after CD, which could be considered when evaluating surgical indications and providing preoperative counseling to patients.
DOI: 10.6084/m9.figshare.30284521.v1
title: Association of the systemic immune inflammation index with failure after core decompression for osteonecrosis of the femoral head: a prospective time-to-event analysis

description: This study aimed to assess the association between preoperative systemic immune inflammation index (SII) and failure after core decompression (CD). We conducted a prospective study of patients admitted to a tertiary referral hospital with osteonecrosis of the femoral head who underwent CD between October 1, 2014 and April 30, 2019, and provided a minimum 3-year follow-up assessment. Restricted cubic splines assessed the dose–effect relationship between SII and failure. Propensity score matching (PSM) balanced potential preoperative confounders. Kaplan–Meier analyses estimated cumulative incidence as a function of time for the failure between low SII and high SII groups. Multivariable Cox proportional hazards models evaluated the independent association of high SII with failure after adjustment for perioperative factors. Prespecified subgroup analyses explored heterogeneity. We found a positive relationship between the preoperative SII and failure after CD. Among 963 CD procedures performed in 676 patients, failure was observed in 97 cases in a median period of 5.4 years. The cumulative incidence of failure was 10.6% (95% CI, 8.7%, 12.8%) at 5 years. After PSM, failure rates at 5 years were identified as significant differences between the high SII and low SII groups (Log-rank p = 0.019), and that high SII was independently associated with a 1.90-fold (95% CI, 1.14, 3.18; p = 0.014) increased risk of failure. Significant heterogeneity was observed by gender and aetiology (P for interaction &lt; 0.05). Preoperative high SII is a significant risk factor for failure after CD, which could be considered when evaluating surgical indications and providing preoperative counseling to patients.
DOI: 10.6084/m9.figshare.30273785
title: Evaluation of the diagnostic efficacy of different glycemic markers and insulin indices for diabetes mellitus in a general population

description: We aimed to assess the contribution of repeated fasting blood glucose (FBG) measurements along with single collection of 2-hour postprandial glucose (2h PG) and glycated hemoglobin (HbA1c) on diabetes mellitus (DM) prevalence estimation, and investigate the association between the insulin-related markers and DM risk in a southeastern Chinese population. We included 6515 participants aged 35–75 years with complete glycemic data. McNemar’s test was utilized to compare the difference between WHO and ADA criteria in DM diagnosis. Newly diagnosed DM cases were classified as 1defect (DEF), 2DEF, or 3DEF DM according to the abnormalities of three glycemic indices. The sensitivity and specificity of diagnosing DM using different glycemic markers were assessed. The association between different index and DM was analyzed using log-binomial regression and receiver operating characteristic curves. The age- and sex-standardized prevalence of DM was 14.0% and 14.7% by the WHO and ADA criteria, respectively. 2h PG, HbA1c, and FBG detected 89.65%, 40.69%, and 15.24% of newly diagnosed DM population, respectively. . All cases identified by repeated FBG were also detected by either 2h PG or HbA1c. The disposition index showed the highest area under the curve (0.82) in DM prediction, followed by the product of triglyceride and fasting glucose (TyG, 0.72). The estimated previous diagnosis, treatment, and control rate of DM was 38.6%, 34.9%, and 29.4%, respectively. It is recommended that 2h PG and HbA1c should be used in population-based studies. The disposition index and TyG could potentially be used as DM predictors. 2h PG plays a pivotal role in the identification of a substantial proportion of DM patients, while HbA1c can serve as an adjunctive tool to support the diagnosis.The disposition index and TyG can be used as potential predictor indicator for DM.The discrepancy between the WHO and ADA criteria was slight on the estimation of DM prevalence, but apparent on the estimation of prediabetes prevalence. 2h PG plays a pivotal role in the identification of a substantial proportion of DM patients, while HbA1c can serve as an adjunctive tool to support the diagnosis. The disposition index and TyG can be used as potential predictor indicator for DM. The discrepancy between the WHO and ADA criteria was slight on the estimation of DM prevalence, but apparent on the estimation of prediabetes prevalence.